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Abstract: The myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem 
cell diseases characterized by cytopenia(s), dysplasia in one or more of the major myeloid cell 
lines, ineffective hematopoiesis, and increased risk of development of acute myeloid leukemia. 
The classification and the diagnostic criteria have been redefined by the recent World Health 
Organization Classification of Tumors – International Agency for Research on Cancer for 
Hematopoietic and Lymphoid Tissues. The myelodysplastic syndromes are now classified into 
the following categories – refractory cytopenia with unilineage dysplasia, refractory anemia 
with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with 
excess blasts, myelodysplastic syndrome associated with isolated del (5q), myelodysplastic 
syndrome – unclassifiable, and childhood myelodysplastic syndrome. The clinicopathologic 
features, morphology, differential diagnosis, immunophenotyping, cytogenetics, prognosis and 
predictive factors are presented in the light of recent World Health Organization Classification 
of Tumors – International Agency for Research on Cancer.
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Introduction
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell 
diseases characterized by cytopenia(s), dysplasia in one or more of the major myeloid 
cell lines, ineffective hematopoiesis, and increased risk of development of acute myeloid 
leukemia (AML).1–3 The thresholds for cytopenia(s) as recommended in the International 
Prognostic Scoring System (IPSS) for risk stratification in the MDS are hemoglobin 
,10 g/dl, absolute neutrophil count (ANC) ,1.8 × 109/L and platelets ,100 × 109/L.4,5 
Values above these thresholds are not exclusionary for a diagnosis of MDS if definitive 
morphologic or cytogenetic findings are present.6 Myeloblasts in the peripheral blood 
and bone marrow are ,20%. A working group of the World Health Organization (WHO) 
recently proposed a new classification of MDS (Table 1), based on a significant modi-
fication of the original FAB proposals. The classification system as proposed by FAB 
included the following subtypes – refractory anemia (RA), refractory anemia with ring 
sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia 
with excess blasts in transformation (RAEBT), and chronic myelomonocytic leukemia 
(CMML). In the recent WHO classification, CMML and RAEB-T were removed from Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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the MDS classification and RAEB was split into two groups 
with medullary blast counts below and above 10%. In addi-
tion, a group of patients with less than 5% medullary blasts 
but evidence of multilineage dysplasia was defined. MDS 
patients with 5q − as the sole chromosomal anomaly were 
also considered a separate group. There is a significant dif-
ference in prognosis between RAEB I and RAEB II, as well 
as a difference between refractory anemia and multilineage 
dysplasia. Furthermore, patients with 5q − anomaly had a 
much better prognosis than other WHO subtypes, but this 
was only true for patients with a medullary blast count below 
5%. In summary, the WHO classification appears to define 
morphological subgroups that are more homogeneous with 
respect to prognosis than the FAB subtypes.
Although progression to AML is the natural course in 
many cases of MDS, the percentage of patients who prog-
ress varies substantially in the various subtypes. A higher 
percentage of patients with increased myeloblasts transforms 
into AML.7,8 The recurring chromosomal abnormalities 
and their frequency in MDS at diagnosis is illustrated in 
Table 2A scoring system for predicting survival and evolution 
to AML based on percent of BM blasts, type of cytogenetic 
abnormalities, and degree and number of cytopenias has been 
proposed by International Prognostic Scoring System (IPSS) 
for MDS4,5 (Table 3). Treatment is based on several factors 
including age, prior history of a myelodysplastic syndrome, 
overall clinical assessment and tempo of the process.
The annual incidence of myelodysplastic syndromes 
is 3–5/100000 persons but rising to .20/100000 among 
those over the age of 70 years.9,10 MDS principally occurs in 
older adults with a median age of 70 years. There is a male 
predominance.
Clinical features
The majority of patients present with symptoms related to 
cytopenia(s) – hemorrhage, recurrent infection, fatigue, 
  dyspnea, gingival bleeding and hematomas. Most patients 
are anemic and transfusion dependent.11 Less frequent 
are   neutropenia or thrombocytopenia. Organomegaly is 
  infrequently observed. Approximately 10%–40% of the 
Table 1 Recent WHO 2008 classification of myelodysplastic syndromes11
Disease Blood findings Bone marrow findings
Refractory cytopenia with 
unilineage dysplasia (RCUD) 
Refractory anemia (RA);  
Refractory neutropenia (RN);  
Refractory thrombocytopenia (RT)
Unicytopenia or bicytopenia$  
No or rare blasts (,1%)#
Unilineage dysplasia:  
$10% of cells in one myeloid lineage  
,5% blasts  
,15% erythroid 
precursors are ring sideroblasts
Refractory anemia with ring 
sideroblasts (RARS)
Anemia  
No blasts
.15% erythroid precursors are ring sideroblasts 
erythroid dysplasia only ,5% blasts
Refractory cytopenia with 
multilineage dysplasia (RCMD)
Cytopenia(s)  
No or rare blasts (,1%)# 
No Auer rods  
,1 × 109/L monocytes 
Dysplasia in .10% of cells in  
$two myeloid lineages  
,5% blasts in marrow No Auer rods 
±15% ring sideroblasts
Refractory anemia with excess 
blasts-1 (RAeB-1)
Cytopenia(s)  
,5% blasts#  
No Auer rods  
,1 × 109/L monocytes 
Unilineage or multilineage dysplasia  
5%–9% blasts# 
No Auer rods 
Refractory anemia with excess 
blasts-2 (RAeB-2)
Cytopenia(s)  
5%–19% blasts  
Auer rods ± 
,1 × 109/L monocytes 
Unilineage or multilineage dysplasia  
10%–19% blasts 
Auer rods ± 
Myelodysplastic 
syndrome – unclassified (MDS-U)
Cytopenias  
,1% blasts#
Unequivocal dysplasia in less than 10% of cells  
in one or more myeloid cell lines when 
accompanied by cytogenetic abnormality 
considered as presumptive evidence for  
diagnosis of MDS ,5% blasts
MDS associated with isolated 
del (5q)
Anemia  
Usually normal or increased 
platelet count  
No or rare blasts (,1%)
Normal to increased megakaryocytes with 
hypolobated nuclei ,5% blasts isolated del (5q) 
cytogenetic abnormality  
No Auer rods
Notes: $Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U.
#if the marrow myeloblast percentage is ,5% but there are 2%–4% myeloblasts in the blood, the diagnostic classification is RAEB-1. Cases of RCUD and RCMD with 1% 
myeloblasts in the blood should be classified as MDS, U.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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patients progress to AML and 20%–40% of the patients die 
of infection or bleeding, or both.
Etiology
Primary MDS occurs without a known history of chemo-
therapy or radiation exposure. Possible etiologies for primary 
MDS include benzene exposure at levels above the minima 
allowed by most government agencies,   cigarette smoking, 
exposure to agricultural chemicals or solvents and family 
  history of hematopoietic neoplasms.12   Secondary MDS is 
  usually seen under 50 years of age and is due to   chemotherapy, 
radiation therapy or environmental mutagens.
Morphology
The morphological classification of MDS is principally 
based on the percent of blasts in the bone marrow (BM) and 
peripheral blood (PB), the type and degree of dysplasia and 
the presence of ring sideroblasts.1 To determine the blast 
percentage in the BM, a 500-cell differential of all nucleated 
cells in a smear or trephine imprint is recommended and in 
the PB, a 200-leukocyte differential. In severely cytopenic 
patients, buffy coat smears of PB may facilitate performing 
the differential. The characteristics of dysplasia are relevant 
when distinguishing between various types of MDS and 
may be important in predicting biology. Persistent cytopenia 
without dysplasia and without one of the specific cytogenetic 
abnormalities considered as presumptive evidence of MDS 
should be viewed as the recently described “idiopathic 
cytopenia of undetermined significance” (ICUS).13 The 
recommended requisite percentage of cells manifesting 
dysplasia to qualify as significant is $10% in the erythroid 
precursors and granulocytes.14 Significant megakaryocyte 
dysplasia is defined as $10% dysplastic megakaryocytes 
based on evaluation of at least 30 megakaryocytes in smears 
or sections. Dyserythropoiesis is manifest principally by 
alterations in the nucleus including budding, internuclear 
bridging, karyorrhexis, multinuclearity (Figure 2A, 2B 
and 2C) and megaloblastoid changes (Figure 2A and 2B); 
cytoplasmic features include ring sideroblasts, vacuoliza-
tion and periodic acid-Schiff positivity, either diffuse 
or granular.   Dysgranulopoiesis is characterized primar-
ily by nuclear hypolobation (pseudo Pelger–Huet) and 
  hypersegmentation, cytoplasmic hypogranularity, pseudo 
  Chediak–  Higashi   granules and small size. Megakaryocyte 
dysplasia is   characterized by micro-megakaryocytes with 
hypolobated nuclei, nonlobated nuclei in megakaryocytes 
of all sizes, and multiple, widely separated nuclei. The 
characteristics of dysplasia may be relevant in predicting 
biology of   myelodysplastic disorder and the relationship to 
specific cytogenetic abnormalities, eg, 5q-syndrome.6 The 
significance of Auer rod in myeloid   disorders is uncertain. 
In the revised FAB classification of 1982 it was viewed 
as evidence of a high grade MDS,   refractory anemia with 
excess of blasts in transformation (RAEBT), irrespective of 
the blast percentage in the PB or BM.1 In the prior WHO 
Classification of the MDS it was considered as evidence of 
RAEB-2 or CMML-2 in the context of MDS/MPN regardless 
of blast percentage. This concept is retained in the present 
classification. The BM in MDS is usually hypercellular or 
normocellular; the cytopenias result from the ineffective 
hematopoiesis. Histologically, aggressive MDS may be char-
acterized by the presence of aggregates (3–5 cells) or clusters 
(.5 cells) of blasts in BM biopsies usually localized in the 
central portion of the BM away from the vascular structures 
and endosteal surfaces of the bony trabeculae. These are 
frequently present in RAEB.
Other investigations reveal normal-to-high serum iron and 
folic acid levels. The Total Iron Binding Capacity (TIBC) may 
be normal-to-decreased. There is a decrease in the number of 
T-lymphocytes (CD4 and CD8) while the B-lymphocytes are 
quantitatively normal. Serum immunoglobulins are increased 
and circulating immune complexes are frequently present.15
Differential diagnosis
Several nutritional, toxic and other factors including 
  essential element deficiencies and exposure to heavy metals, 
Table  2  Recurring  chromosomal  abnormalities  and  their 
frequency in myelodysplastic syndromes at diagnosis11
Abnormality MDS t-MDS
Unbalanced
+8 10%
−7 or del (7q) 10% 50%
−5 or del (5q) 10% 40%
del (20q) 5%–8%
−Y 5%
i(17q) or t(17p) 3%–5%
−13 or del (13q) 3%
del (11q) 3%
del (12p) or t(12p) 3%
del (9q) 1%–2%
idic(X)(q13) 1%–2%
Balanced
t(11;16)(q23;p13.3) 3%
t(3;21)(q26.2;q22.1) 2%
t(1;3)(p36.3;q21.2) 1%
t(2;11)(p21;q23) 1%
inv(3)(q21q26.2) 1%
t(6;9)(p23;q34) 1%
Abbreviation: MDS, myelodysplastic syndrome.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Gupta et al
  particularly arsenic and several commonly used drugs and 
biologic agents may cause myelodysplastic changes.16 Other 
causes for dyserythropoiesis include congenital hematologi-
cal disorders, Parvovirus B19 infection and immunosuppres-
sive agent mycophenolate mofetil. Chemotherapeutic agents 
may result in marked dysplasia of all myeloid cell lineages. 
Paroxysmal nocturnal hemoglobinuria may also present with 
features similar to MDS.
Variants
Hypoplastic MDS
In approximately 10% of the cases the BM is hypocellular. 
These cases have been referred to as hypoplastic MDS. The 
BM cellularity is ,30% or ,20% in patients over 60 years 
of age. This group has no individual prognostic significance. 
The differential diagnosis for this group includes aplastic 
anemia, toxic myelopathy and autoimmune disorders. 
  Antithymocyte globulin and other therapies used for aplastic 
anemia are used as treatment options in this subgroup.16
MDS with myelofibrosis
Significant degrees of myelofibrosis are observed in 
  approximately 10% of the cases of MDS. These cases have 
been referred to as MDS with fibrosis.17 Most of these cases 
have an excess of blasts and an aggressive clinical course. 
Laboratory investigations reveal pancytopenia,   hypocellular 
bone marrow with fibrosis, trilineage dysplasia, small 
  megakaryocytes with hypolobated nuclei and absence of 
AB
Figure 1 Refractory cytopenia with unilineage dysplasia (RCUD). Bone marrow aspirate (wright–Giemsa – 100x). A) Refractory anemia – showing dyserythropoiesis with 
cytoplasmic vacuolation. B) Refractory thrombocytopenia – showing dysmegakaryopoiesis with multinucleation.
A
B
C
Figure 2 A) Leishman Stain (×100 magnification). Showing dyserythropoiesis. B) May–Grunwald Giemsa Stain (×100 magnification). Arrow showing binucleate erythroblast. 
C) Leishman Stain (×200 magnification). Showing multinucleate erythroblast and erythroid dysplasia.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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hepatomegaly with prominent splenomegaly. Increase in 
fibrosis is due to liberation of cytokines such as TGF-β and 
PDGF from dysplastic megakaryocytes.15 The differential 
diagnosis includes myelofibrosis with myeloid metaplasia, 
chronic myelocytic leukemia and acute megakaryocytic 
leukemia.
Classification
Refractory cytopenia  
with unilineage dysplasia
Refractory anemia with unilineage dysplasia (RCUD) is 
intended to encompass those myelodysplastic syndromes 
which present with a refractory cytopenia with unilineage 
dysplasia and includes refractory anemia (RA), refrac-
tory neutropenia (RN) and refractory thrombocytopenia 
(RT). Refractory bicytopenia may be included in the 
RCUD   category if accompanied by unilineage dysplasia. 
  Refractory pancytopenia is placed in a category of myelo-
dysplastic   syndrome, unclassifiable (MDS-U). The recom-
mended level for dysplasia is $10% of the cell lineage 
affected. The   recommended levels for defining cytopenias 
are hemoglobin ,10 g/dL, absolute neutrophil count 
(ANC) ,1.8 × 109/L and platelet count ,100 × 109/L.4,5 
The presence of peripheral blood blasts essentially excludes 
a diagnosis of RCUD although in an occasional case a rare 
blast may be identified.
Refractory cytopenia with unilineage dysplasia   comprises 
10%–20% of the cases of MDS.18 The median age of 
  presentation is around 65–70 years. There is no significant sex 
predilection. Majority of the RCUD cases are RA. Refractory 
neutropenia and refractory thrombocytopenia are rare. The 
presenting symptoms are related to the type of cytopenia.
Refractory anemia
The peripheral blood picture in refractory anemia shows 
  normocytic or macrocytic with normochromic red blood 
cells. There is variable anisopoikilocytosis. Blasts are rarely 
seen and if present, account for ,1% of the white blood cells. 
The neutrophils and platelets are usually normal in number 
and morphology. The bone marrow is usually hypercellular 
with erythroid hyperplasia. Dyserythropoiesis varies from 
slight to moderate with evidence of dysplasia in 10% or 
more of the erythroid precursors (Figure 1A, 2A, 2B, 2C). 
Ring sideroblasts may be present but are ,15% of erythroid 
precursors. Myeloblasts account for ,5% of the nucleated 
BM cells. The neutrophils and megakaryocytes are normal 
or may show minimal dysplasia, but always ,10% in either 
cell line.
Cytogenetic abnormalities associated with RA include 
del (20q), +8 and abnormalities of chromosome 5 and/or 
chromosome 7. Approximately 90%–95% of patients with 
refractory anemia have low or intermediate International 
Prognostic Scoring System (IPSS).4,5
Refractory neutropenia
Refractory neutropenia is characterized by $10% dysplastic 
neutrophils in the peripheral blood or bone marrow. The 
dysplasia principally manifests as nuclear hypolobation and 
hypogranulation. The other myeloid cell lines do not show 
significant dysplasia (,10%).
Refractory thrombocytopenia
Refractory thrombocytopenia is characterized by $10% 
dysplastic megakaryocytes of at least 30 megakaryocytes 
evaluated. The dysplasia principally manifests as hypolobate 
megakaryocytes, binucleate and multinucleate megakaryo-
cytes and micromegakaryocytes (Figure 1B). The other myel-
oid cell lines do not show significant dysplasia (,10%).
Most patients with refractory thrombocytopenia have 
low IPSS scores and 90% of the patients live more than two 
years.19
Refractory anemia with ring sideroblasts
Refractory anemia with ring sideroblasts (RARS) is a 
myelodysplastic syndrome (MDS) characterized by anemia, 
morphologic dysplasia in the erythroid lineage and ring 
sideroblasts comprising $15% of the bone marrow erythroid 
precursors. There is no significant dysplasia in the noneryth-
roid lineages. Myeloblasts comprise ,5% of the nucleated 
BM cells and are not present in the peripheral blood.
RARS accounts for 3%–11% of the MDS cases. The 
median age of presentation is 60–73 years with no sex 
predilection. Primary defects of heme synthesis can largely 
be excluded because protoporphyrin IX, the end product of 
porphyrin synthesis, is not decreased in RARS.20 Acquired 
mutations in genes of the heme synthetic pathway have 
not been   demonstrated in RARS. Thus a primary defect of 
  mitochondrial iron metabolism is suspected. RARS repre-
sents a clonal stem cell defect that manifests as abnormal iron 
metabolism in the erythroid lineage and results in ineffective 
erythropoiesis. The PB and BM are the principal sites of 
involvement. The liver and spleen may show signs of iron 
overload. Patients present with symptoms related to anemia 
and progressive iron overload.
The peripheral blood picture shows a normochromic 
macrocytic or normochromic normocytic anemia. Blasts are Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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not present in the PB (Figure 3A). The BM aspirate smear 
shows increase in the number of erythroid   precursors with 
erythroid lineage dysplasia (Figure 3B). Granulocytes and 
megakaryocytes show no significant dysplasia (,10% dys-
plastic forms). Hemosiderin laden macrophages are often 
abundant. On an iron stained aspirate smear, 15% or more 
of the red cell precursors are ring sideroblasts (Figure 3C). 
The BM biopsy is normocellular to markedly hypercellular, 
usually with marked erythroid proliferation. Megakaryocytes 
are normal in number and morphology.
Clonal chromosomal abnormalities are seen in 5%–20% 
of cases of RARS and when present, typically involve a 
single chromosome.21 Approximately 1%–2% of cases of 
RARS evolve to acute myeloid leukemia. The overall median 
  survival is 69–108 months.
Refractory cytopenia  
with multilineage dysplasia
Refractory cytopenia with multilineage dysplasia (RCMD) 
is a type of myelodysplastic syndrome with one or more 
  cytopenias and dysplastic changes in two or more of the 
myeloid lineages: erythroid, granulocytic,   megakaryocytic.14 
There are ,1% blasts in the peripheral blood and ,5% 
in the bone marrow. Auer rods are not present and the 
  monocytes in the peripheral blood are less than 1 × 109/L. 
The   recommended levels for defining cytopenias are hemo-
globin ,10 g/dL, absolute neutrophil count ,1.8 × 109/L 
and platelet count ,100 × 109/L.4,5 The thresholds for 
  dysplasia are $10% in each of the affected cell lines. At 
least 30 megakaryocytes should be evaluated for dysplasia 
in BM smears or sections.
RCMD accounts for 30% of cases of MDS. The median 
age is approximately 70 years. There is a slight predominance 
of males. The peak incidence for males is 70–74 years, for 
females 75–79 years.18 Blood and bone marrow are the 
principal sites of involvement. Most of the patients present 
with evidence of BM failure with cytopenia of two or more 
myeloid cell lines.
The BM is usually hypercellular. Myeloblasts account for 
,5% of the BM cells. Neutrophil dysplasia is   characterized by 
hypogranulation and nuclear hyposegmentation with marked 
clumping of nuclear chromatin (pseudo   Pelger–Huet nuclei) 
(Figure 4). Erythroid precursors may show cytoplasmic vacu-
oles and marked nuclear irregularity. The vacuoles may be 
periodic acid-Schiff (PAS) positive. There may also be diffuse 
cytoplasmic PAS positivity. Megakaryocyte abnormalities 
include nonlobated nuclei, hypolobated nuclei, binucleate 
or multinucleate megakaryocytes and micromegakaryocytes. 
Micromegakaryocytes are the most reliable and reproducible 
dysplastic feature in the megakaryocyte series.22
Clonal cytogenetic abnormalities including trisomy 8, 
monosomy 7, del (7q), monosomy 5, del (5q), and del (20q) 
as well as complex karyotypes, may be found in up to 50% 
of patients with RCMD.18,4
A BC
Figure 3 Refractory anemia with ringed sideroblasts (RARS). A) Peripheral blood smear (wright–Giemsa – 100x). Occasional macro-ovalocytes seen. B) Bone marrow 
biopsy specimen (H&E stain – 100x). Erythroid hyperplasia with immature erythroid cells. C) iron stain – 100x. with ringed sideroblasts.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Refractory anemia with excess blasts
Refractory anemia with excess blasts (RAEB) is a 
myelodysplasyic syndrome with 5%–19% myeloblasts in 
the bone marrow or 2%–19% blasts in the peripheral blood. 
Due to differences in survival and incidence of evolution to 
acute myeloid leukemia (AML), two categories of RAEB are 
recognized: RAEB-1, defined by 5%–9% blasts in the BM 
(Figure 5A, 5B) or 2%–4% blasts in the PB, and RAEB-2, 
defined by 10%–19% blasts in the BM or 5%–19% blasts in 
the PB.4 The presence of Auer rods in blasts qualifies a case as 
RAEB-2 (Figure 5C) irrespective of the blast percentage.7
RAEB accounts for approximately 40% of all patients 
with MDS. It affects individuals above 50 years of age. 
Risk factors include exposure to environmental toxins; 
such as pesticides, petroleum derivatives, some heavy met-
als, and cigarette smoking. RAEB principally involves the 
blood and bone marrow. Patients present with symptoms 
related to BM failure, including anemia, thrombocytopenia 
and neutropenia.
The peripheral blood smear frequently shows abnormalities 
in all three myeloid cell lines, including red cell anisopoikilo-
cytosis; large, giant or hypogranular platelets and abnormal 
cytoplasmic granularity and nuclear   segmentation of the 
neutrophils. Blasts are commonly present in the PB. The 
bone marrow is usually hypercellular with varying degrees 
of dysplasia. Erythropoiesis may be increased with mac-
rocytic or megaloblastoid changes. Granulopoiesis and 
  megakaryopoiesis are frequently increased with varying 
degrees of dysplasia. The megakaryocytes often show a ten-
dency to cluster. In the BM biopsy, both erythropoiesis and 
megakaryopoiesis appear frequently dislocated towards the 
paratrabecular areas that are normally predominantly occu-
pied by granulopoietic cells. Blasts in RAEB often tend to 
form cell clusters or aggregates that are usually located away 
from bone trabeculae and vascular structures, a   histologic 
finding commonly referred to as abnormal localization of 
immature precursors (ALIP) (Figure 5D). These may be 
identified by immunohistochemical staining for CD34.
Flow cytometry shows increased number of cells positive 
for CD34 and CD117. These cells are usually positive for 
CD38, HLA-DR and myeloid associated antigens CD13 and 
CD33. Asynchronous expression of granulocytic maturation 
antigens CD15, CD11b and CD65 can be seen in the blast 
population. Antibodies such as CD61 or CD42b can aid in 
the identification of micromegakaryocytes and other small 
dysplastic forms, which are particularly numerous in cases 
of RAEB-F.17
Clonal cytogenetic abnormalities are present in 30%–50% 
cases of RAEB. These include +8, −5, del (5q), −7, del (7q) 
and del (20q). Approximately 25% of cases of RAEB-1 and 
33% of patients with RAEB-2 progress to AML, the remain-
der succumb to sequelae of BM failure. The median survival 
is approximately 16 months for RAEB-1 and 9 months for 
RAEB-2.
RAEB with fibrosis (RAEB-F)
The current working definition of MDS with fibrosis (MDS-F) 
requires diffuse coarse reticulin fibrosis with or without 
concomitant collagenization, associated with dysplasia in 
at least two cell lineages.23 Most of the cases defined as 
MDS-F belong to the RAEB category. The presence of excess 
blasts can be demonstrated using immunohistochemistry for 
CD34. A characteristic finding in RAEB-F is an increased 
number of megakaryocytes of different cell sizes and a high 
degree of dysplasia.17 The differential diagnosis includes 
therapy-related MDS, myeloproliferative neoplasms, acute 
panmyelosis with myelofibrosis (APMF) and rarely reactive 
dyshematopoietic conditions.
Myelodysplastic syndrome  
with isolated del (5q)
Myelodysplastic syndrome with isolated del (5q) is a MDS 
characterized by anemia with or without other cytopenias 
and/or thrombocytosis and in which the sole cytogenetic 
abnormality is del (5q). Myeloblasts comprise ,5% of 
nucleated BM cells and ,1% of peripheral blood leukocytes 
and Auer rods are absent.
The median age of presentation is 67 years and occurs 
more often in women. The etiology includes presumed loss 
of tumor suppressor gene in the deleted region. Possible 
candidates include early growth response 1 (EGR1) and 
Figure 4 Refractory cytopenia with multilineage dysplasia (RCMD). Bone marrow 
aspirate (wright–Giemsa stain – 100x). erythroid precursors with nuclear irregularity 
and myeloid precursors with hypogranulation and hyposegmentation.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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α-catenin (CTNNA1) genes. The RPS 14 gene that encodes 
a ribosomal protein (40S subunit) has been proposed as 
a candidate in the 5q-syndrome, raising the possibility 
that a defect in the ribosomal protein function causes the 
disorder.11 The gene haploinsufficiency blocks the process-
ing of the preribosomal RNA and the formation of 40S 
subunit. Forced expression of RPS 14 in primary bone 
marrow cells from patients with the 5q-syndrome rescues 
the phenotype.24
The principal sites of involvement are blood and 
bone marrow. The most common symptoms are related 
to anemia, which is often severe and usually macrocytic. 
Thrombocytosis is present in one-third to one-half of patients, 
while thrombocytopenia is uncommon.25
The bone marrow is usually hypercellular or normocellular 
and frequently exhibits erythroid hypoplasia. Megakaryocytes 
are increased in number and are normal to slightly decreased 
in size with nonlobated or hypolobated nuclei (Figure 6). 
In contrast, dysplasia in erythroid and myeloid lineages is 
uncommon.25
The sole cytogenetic abnormality involves an interstitial 
deletion of chromosome 5; the size of the deletion and 
breakpoints are variable, but bands q31–q33 are invari-
ably deleted. Any additional cytogenetic abnormality if 
present, (with the exception of loss of Y chromosome), 
the case should not be placed in this   category. It has been 
recently reported that a small subset of patients with iso-
lated del (5q) may show concomitant JAK2 V617F muta-
tion.11 The disease is associated with a median   survival 
of 145 months, with transformation to AML occurring in 
,10% of patients.25 The thalidomide analog   lenalidomide 
has been shown to benefit MDS patients with isolated 
del (5q) as well as del (5q) with additional cytogenetic 
abnormalities.
Myelodysplastic syndrome, unclassifiable
Myelodysplastic syndrome, unclassifiable (MDS-U) is a 
subtype of MDS which initially lacks findings appropriate 
for classification into any other MDS category.
The incidence of MDS-U is unknown. The peripheral 
blood and bone marrow are the principal sites of involve-
ment. Patients present with symptoms similar to those seen 
in other myelodysplastic syndromes.
There are no specific morphologic findings. The   diagnosis 
of myelodysplastic syndrome, unclassifiable is made in 
the following three instances: i) Patients with findings of 
refractory cytopenia with unilineage dysplasia or refractory 
cytopenia with multilineage dysplasia but with 1% blasts in 
the peripheral blood, ii) cases of MDS with unilineage dyspla-
sia which are associated with pancytopenia, iii) patients with 
persistent cytopenia with 1% or fewer blasts in the blood and 
fewer than 5% in the BM, unequivocal dysplasia in less than 
10% of the cells in one or more myeloid lineages, and who 
have cytogenetic abnormalities considered as a presumptive 
evidence of MDS.26
In cases diagnosed as MDS-U, it is unknown both 
percentage of patients which transform to acute myeloid 
leukemia as well as the disease survival.
A B
C D
Figure 5 Refractory anemia with excess blasts (RAeB). Bone Marrow (A, B) Aspirate (wright–Giemsa – 100x) showing blasts, RAeB-1. C) Aspirate (wright–Giemsa – 100x) 
Blasts with Auer rods, RAeB-2. D) Biopsy (H&E stain – 40x), Abnormal localization of immature precursors (ALIP).Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Childhood myelodysplastic syndrome
Myelodysplastic syndrome is very uncommon in   children, 
accounting for less than 5% of all hematopoietic neoplasms 
in patients less than 14 years of age. Refractory   cytopenia 
of childhood (RCC) is a myelodysplastic syndrome 
  characterized by persistent cytopenia with ,5% blasts 
in the bone marrow and ,2% blasts in the peripheral 
blood.27
RCC is the most common subtype of MDS in child-
hood accounting for about 50% of the cases. It is diagnosed 
in all age groups and affects boys and girls with equal 
frequency. Blood and bone marrow are always affected. 
  Generally, spleen, liver and lymph nodes are not sites of 
initial   manifestation. The most common symptoms are 
malaise, bleeding, fever and infection. Lymphadenopathy 
may be present. In up to 20% of patients no clinical signs 
or   symptoms are reported.28 Congenital abnormalities of 
different organ systems may be present.
The classical picture of RCC is a peripheral blood 
smear that shows red blood cell anisopoikilocyto-
sis and   macrocytosis. Anisochromia may be present. 
Hemoglobin ,10 g/dL is noted in about half of the affected 
children. Three quarters of patients have a platelet count 
below 150 × 109/L. Platelets often display anisocytosis and 
occasionally giant platelets may be detected. Neutropenia 
with pseudo-  Pelger–Huet nuclei or hypogranularity of 
  neutrophil cytoplasm may be noted. Blasts are absent or 
account for less than 2% of the white blood cells. On bone 
marrow aspirate smears dysplastic changes should be present 
in two different myeloid cell lineages, or exceed 10% in one 
single cell line. Myeloblasts account for fewer than 5% of 
bone marrow cells. Megakaryocytes are usually absent or 
very low in number. The detection of micromegakaryocytes 
is a strong indicator of RCC (Figure 7). Ring sideroblasts are 
not found. About 75% of children with RCC show consider-
able hypocellularity of the bone marrow, down to 5%–10% 
of the normal age matched value. The morphologic findings 
are similar to those observed in the normally cellular or 
hypercellular cases.
Monosomy 7 is the most common cytogenetic abnor-
mality. Other cytogenetic abnormalities including complex 
karyotypes may also be observed. Patients with monosomy 
7 have a significantly higher probability of progression than 
patients with other chromosomal abnormalities or normal 
karyotype. Immunosuppressive therapy can be a successful 
therapy strategy for improving outlook in some children 
with RCC.
Micromegakaryocytes are readily appreciated by the 
expression of platelet glycoproteins like CD61 (glycoprotein 
IIIa), CD41 (glycoprotein IIb/IIIa) or von Willebrand fac-
tor. Myeloblasts are positive for CD34, myeloperoxidase, 
lysozyme and CD117.
A B
C D
Figure 6 Myelodysplastic syndrome with isolated del (5q). A, B) Bone marrow aspirate (40x and 100x). Hypolobated megakaryocyte seen. C, D) Bone marrow     
biopsy – (10x and 40x – H&E stain). Hypercellular bone marrow with myeloid proliferation associated with hypolobated or nonlobated megakaryocytes.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Cytochemistry and 
immunophenotyping
Peroxidase and Sudan black B identify blasts with a myel-
oid origin, however, in MDS the blasts may have a lower 
  peroxidase activity than normal blasts. Combined esterase 
stain may be performed on both peripheral blood and bone 
marrow for a more accurate assessment of monocytic 
cells. Iron stain may reveal abnormal iron metabolism in 
erythroblasts with the presence of increased iron stores and 
ringed sideroblasts. Abnormal carbohydrate metabolism 
is   indicated by the presence of blocks of PAS-positive 
material in erythrocyte precursors. Abnormal small 
megakaryocytes are identified by immunochemistry with 
antibodies against platelet-specific glycoproteins IIb/IIIa 
(CD41), GPIIIa (CD61), or by antibody against factor VIII 
in histologic sections. Diaminobenzidine can be utilized 
to identify platelet peroxidase in electron micrographs.15,17 
Erythroid abnormalities can be determined by the pat-
tern of expression of H-Ferritin, CD71 and CD105 in 
glycophorin A (GPA) positive nucleated cells. Increased 
expression of markers found on immature myeloid cells 
such as CD13, CD33, CD34, and HLA-DL and decreased 
expression of NAT-9 (found on mature myeloid cells) may 
be associated with a worse prognosis and with   progression 
to AML.15
Cytogenetics
Cytogenetic and molecular studies have a major role in the 
evaluation of patients with MDS in regard to   prognosis, 
determination of clonality, and the recognition of   cytogenetic, 
morphologic, and clinical correlates. Clonal cytogenetic 
abnormalities are observed in around 50% of MDS cases. 
The recurring chromosomal abnormalities and their 
  frequency in MDS at diagnosis is illustrated in Table 2. The 
types of   cytogenetic abnormalities seen in MDS are usually 
  unbalanced in contrast to inversions or translocations seen in 
AML. The more frequent cytogenetic abnormalities involve 
structural or numeric abnormalities of chromosome 5 and 
7 and trisomy 8.15 New techniques such as fluorescence in 
situ hybridization (FISH) have improved the identification 
of chromosome abnormalities using specific DNA probes. 
Three major risk categories of cytogenetic findings have 
been defined by the International Myelodysplastic Syndrome 
Working Group.4 These include: i) good risk – normal 
karyotype, isolated del (5q), isolated del (20q) and − Y; 
ii) poor risk – complex abnormalities, ie, $3 abnormalities, 
or abnormalities of chromosome 7; and iii) intermediate 
risk – all other abnormalities.
Prognosis and predictive factors
A scoring system for predicting survival and evolution 
to AML based on percent of BM blasts, type of cytoge-
netic abnormalities, and degree and number of cytopenias 
has been proposed by International Prognostic Scoring 
System (IPSS) for MDS (Table 3).4,5 Four risk groups 
are recognized based on this scoring system: low, 0; INT 
(intermediate) −1, 0.5–1.0; INT −2, 1.5–2.0; and high, $2.5. 
The median   survival for the low risk group is 5.7 years, for 
  intermediate −1 is 3.5 years, for intermediate −2 is 1.2 years 
and for the high risk group is 0.4 years.15 In general, the 
higher risk groups are related to higher BM blast percent-
age, more unfavorable cytogenetic findings and more severe 
degree of cytopenia. Patients younger than 60 years of age 
have improved survival in the individual risk categories 
compared with patients older than 60 years. The cytogenetic 
subgrouping of the IPSS system also has independent value 
in   predicting the outcome of allogeneic stem cell transplanta-
tion in patients with MDS.29
Treatment
The therapy of MDS has been unsatisfactory. Only stem 
cell transplantation offers cure: survival rates of 50% at 
3 years have been reported, but older patients are particularly 
prone to develop treatment-related mortality and morbidity. 
Results of transplant using matched unrelated donors are 
comparable, although most series contain younger and more 
highly selected cases.30
MDS has been regarded as particularly refractory to 
cytotoxic chemotherapy regimens but is probably no more 
resistant to effective treatment than acute myeloid leukemia 
in the elderly, in whom drug toxicity is often fatal and remis-
sions, if achieved, are brief.
Low doses of cytotoxic drugs have been administered 
for their “differentiating” potential, and from this experience 
has emerged drug therapies based on pyrimidine analogs. 
Table 3 international prognostic scoring system (iPSS) for MDS4,5
Score 0 0.5 1 1.5 2
Prognostic variables
% bone marrow  
blasts
,5% 5%–10% 11%–19% 20%–30%*
Karyotype** Good intermediate Poor
Cytopenias*** 0–1 2–3
Notes: *This group is recognized as AML in the WHO classification; **Karyotype: 
Good = normal, −Y, del (5q), del (20q); Poor = complex ($3 abnormalities) or 
chromosome 7 anomalies; intermediate = other abnormalities; ***Cytopenias: Hgb 
,10 g/dL; Neutrophils ,1.8 × 109/L; Platelets ,100 × 109/L.
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; 
WHO, world health organization.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Azacitidine is directly cytotoxic but also inhibits DNA 
methylation, thereby altering gene expression. Azacitidine 
improves blood counts and modestly improves survival in 
about 16% of MDS patients, compared to best supportive 
care.30 Decitabine is closely related to azacitidine and more 
potent. The major toxicity of both azacitidine and decitabine 
is myelosuppression, leading to worsened blood counts. Other 
symptoms associated with cancer chemotherapy frequently 
occur.
Thalidomide, a drug with many activities including anti-
angiogenesis and immunomodulation, has modest biologic 
activity in MDS. Lenalidomide, a thalidomide derivative 
with a more favorable toxicity profile, is   particularly effec-
tive in reversing anemia in MDS patients with 5q-syndrome; 
not only do a high proportion of these patients become 
  transfusion-independent with normal or near-normal 
  hemoglobin levels, but their cytogenetics also become 
normal.29 Toxicities include myelosuppression (worsening 
thrombocytopenia and neutropenia, necessitating blood count 
monitoring) and an increased risk of deep vein thrombosis 
and pulmonary embolism.
Other treatments for MDS include amifostine, an organic 
thiophosphonate that blocks apoptosis; it can improve blood 
counts but has significant toxicities. Antithymocyte globulin 
and cyclosporine, also may produce sustained independence 
from transfusion, especially in younger MDS patients with 
more favorable International Prognostic Scoring System 
(IPSS) scores.30
Hematopoietic growth factors can improve blood counts 
but, as in most other marrow failure states, have been most 
beneficial to patients with the least severe pancytopenia. 
Erythropoietin alone or in combination with G-CSF can 
improve hemoglobin levels, but mainly in those with low 
serum erythropoietin levels who have no or only a modest 
need for transfusions. RBC transfusion support should be 
accompanied by iron chelation in order to prevent secondary 
hemochromatosis.30
Conclusion
In 1982, the French–American–British (FAB) cooperative 
group proposed a classification of myelodysplastic syn-
dromes (MDS) based on morphological features in blood 
and bone marrow, namely on medullary and peripheral 
blast count, Auer rods, ring sideroblasts and the number 
of   monocytes in the peripheral blood. This classification 
has been used for numerous studies regarding   morphology, 
prognosis and treatment of MDS. Some details of this 
  morphological classification remained unclear, and some 
patients were unclassifiable. Myelodysplastic syndromes 
(MDS) are spectrum of bone marrow failure disorders that 
share a common pathologic feature: cytologic dysplasia. 
The classification of MDS reflects the understanding of 
the disease. The WHO 2008 Classification for MDS has 
been summarized in Table 1. It is hoped that in the future 
  classification and risk stratification will be based on underly-
ing pathobiology of different   disease subsets and molecular 
signatures where the pathologic   classification represents 
their phenotype. This article reviews MDS classification 
and risk stratification highlighting differences between the 
various systems.
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